Meda AB (MDABF.PK) Acquires Exclusive Rights to New Treatment of Actinic Keratosis From Graceway Pharmaceuticals, LLC

5/12/2010 9:56:12 AM

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Meda has acquired exclusive European rights to a new formulation of imiquimod from Graceway Pharmaceuticals. The new formulation is 3,75% imiquimod topical cream indicated for the treatment of actinic keratosis (AK). This product has recently been approved in the US and Canada.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Graceway Pharmaceuticals, LLC

• Meda AB

• Biotech/Pharma - Mergers and Acquisitions

• Biotech/Pharma - Mergers and Acquisitions (World)